.jpeg)
2026-10-23 06:13:37
Vosoritide common reactions are injection-site redness/itching/pain, vomiting, and transient low blood pressure. Eat and hydrate before dosing to reduce dizziness; seek care for severe signs, do not self-adjust.
2026-10-23 06:00:55
Ribociclib is a CDK4/6 inhibitor for HR-positive, HER2-negative breast cancer. Adjuvant use lowers recurrence risk; advanced use controls progression with endocrine therapy. It does not guarantee no metastasis and is not self-managed.
2026-10-23 05:44:41
Pretomanid is a nitroimidazole prodrug activated by mycobacterial Ddn/F420; it inhibits mycolic acid aerobically and poisons respiration anaerobically. Used only with bedaquiline + linezolid for selected adult resistant pulmonary TB.
2026-10-23 05:40:09
Explain the reasons why Parkitinib cannot be used in combination with potent CYP3A4 drugs, as well as the caution and medical signals for patients with bleeding, QT prolongation, and severe infections.
2026-10-22 07:20:42
Pomalidomide is used for multiple myeloma and Kaposi sarcoma and can cause blood cell reductions, infection, and blood clots. This article outlines common side effects, serious warning signs, monitoring, and special precautions.
2026-10-22 07:14:59
Dasatinib is a targeted therapy for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and some cases of Ph+ acute lymphoblastic leukemia (Ph+ ALL). This article outlines adult and pediatric starting doses, how to take the medicine, drug interactions, and long-term monitoring.
2026-10-22 07:09:17
Obeticholic acid 5 mg was once a starting dose for primary biliary cholangitis, but the drug carries a risk of serious liver injury and its US approval was withdrawn in 2025. This article reviews its former role, long-term risks, monitoring, and what patients should do now.
2026-10-22 07:01:57
Acalabrutinib alone can control chronic lymphocytic leukemia in many patients, but remission is not the same as a cure. This article explains how it works, why treatment often continues long term, and what options remain if it stops working.
2026-10-22 06:57:10
FDA approved bepirovsen on 20 Oct 2026 with nucleos(t)ide analogues for non-cirrhotic adults with suppressed HBV DNA and HBsAg ≤3000 IU/mL. B-Well 1/2 showed functional cure in a subset, not viral eradication or all-comer use.
2026-10-21 03:20:56
Ibrutinib resistance does not mean self-escalating dose. Separate true disease progression from toxicity; CLL/SLL may move to venetoclax or non-covalent BTK, MCL may use pirtobrutinib or CAR-T based on prior lines and genomic testing.
2026-10-21 03:14:45
Tucatinib is a selective oral HER2 tyrosine kinase inhibitor, not conventional chemo. It is used in combination regimens for HER2-positive advanced cancer. In breast cancer it is often paired with trastuzumab and capecitabine; HER2 status must be confirmed and diarrhea/liver injury monitored.
2026-10-21 03:08:13
Quizartinib is for adults with newly diagnosed FLT3-ITD-positive AML confirmed by an authorized test; used with cytarabine plus anthracycline induction, cytarabine consolidation, and single-agent maintenance. Not for FLT3-TKD only or post-allo-HSCT maintenance; QT prolongation requires ECG monitoring.
